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Abstract
Understanding the factors, which control ErbB2 and EGF receptor (EGFR) status in cells is likely to inform future therapeutic
approaches directed at these potent oncogenes. ErbB2 is resistant to stimulus-induced degradation and high levels of over-
expression can inhibit EGF receptor down-regulation. We now show that for HeLa cells expressing similar numbers of EGFR
and ErbB2, EGFR down-regulation is efficient and insensitive to reduction of ErbB2 levels. Deubiquitinating enzymes (DUBs)
may extend protein half-lives by rescuing ubiquitinated substrates from proteasomal degradation or from ubiquitin-
dependent lysosomal sorting. Using a siRNA library directed at the full complement of human DUBs, we identified POH1
(also known as Rpn11 or PSMD14), a component of the proteasome lid, as a critical DUB controlling the apparent ErbB2
levels. Moreover, the effects on ErbB2 levels can be reproduced by administration of proteasomal inhibitors such as
epoxomicin used at maximally tolerated doses. However, the extent of this apparent loss and specificity for ErbB2 versus
EGFR could not be accounted for by changes in transcription or degradation rate. Further investigation revealed that cell
surface ErbB2 levels are only mildly affected by POH1 knock-down and that the apparent loss can at least partially be
explained by the accumulation of higher molecular weight ubiquitinated forms of ErbB2 that are detectable with an
extracellular but not intracellular domain directed antibody. We propose that POH1 may deubiquitinate ErbB2 and that this
activity is not necessarily coupled to proteasomal degradation.
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Introduction
The ErbB2/Her2 receptor is one of four members of the ErbB
family of receptor tyrosine kinases (RTKs) [1,2]. Its over-
expression in breast cancers is associated with poor prognosis
and malignancy. It is a high priority drug target, against which
monoclonal antibodies (e.g. Herceptin) are used as a frontline
therapy. The receptor possesses no ligand binding affinity and is
only activated upon ligand-induced hetero-dimerisation with
another family member, for example EGF Receptor (EGFR).
Upon activation, most RTKs are down-regulated through Cbl-
dependent ubiquitination and ubiquitin-dependent sorting to the
lysosome [3]. Uniquely amongst the ErbB family, ErbB2 is
endocytosis defective, with the consequence that its over-
expression may also interfere with the down-regulation of ErbB
family binding partners [4,5,6,7]. To date the influence of ErbB2
on EGFR down-regulation has been studied by over-expression,
but the inverse approach of ErbB2 knock-down has not been
explored.
The ubiquitin system influences nearly all aspects of cell
physiology [8]. It can determine protein stability, by promoting
both proteasomal and lysosomal degradation, but also regulates
transcription and translation. The hsp90 inhibitor Geldanamycin
induces the down-regulation of ErbB2 [9]. Ubiquitination of the
receptor becomes evident and proteasome inhibitors reverse
Geldanamycin-induced degradation [10,11], most likely indirectly
by interfering with lysosomal trafficking of the receptor [12,13,14].
Ubiquitination can be reversed by the action of deubiquitinating
enzymes (DUBs), of which there are around 85 active members
falling into 5 major families [15]. These enzymes are emerging as
attractive drug targets [16].
In this study we have identified a requirement for a DUB
associated with the proteasomal 19S complex, POH1 (also known
as Rpn11 or PSMD14), in the regulation of ErbB2 ubiquitination.
Results
Role of ErbB2 in EGF receptor down-regulation and
signalling
It has been established that SKBr3 cells highly over-express
ErbB2 (2.7610
6) [17] and that HeLa cells possess around 50,000
EGF receptors [18]. Using these estimates as benchmarks, we have
extrapolated relative levels of receptors to other cell lines by
quantitative immuno-blotting using an Odyssey Imaging system.
Thus we can estimate the number of ErbB2 receptors on our
HeLa cells to be in the order of 54,000 and the number of EGFRs
on A549 cells as around 67,000 (Figure 1A and B). Following EGF
stimulation, ErbB2 levels remained constant whilst EGFR levels
declined over a 2 hours time period in HeLa, A549 and DU145
cells (Figure 1B). The degradation rate of EGFR between various
cell lines did not correlate with reduced ErbB2 levels. Degradation
of EGFR in A549 cells is incomplete after 2 hours, yet complete in
HeLa cells, which have a higher ErbB2 to EGFR ratio by an order
of magnitude (Figure 1B). We could not unambiguously detect
PLoS ONE | www.plosone.org 1 May 2009 | Volume 4 | Issue 5 | e5544EGFR in SKBR3 cells; the band seen by Western blotting with
anti-EGFR antibodies is most likely due to minor cross reactivity
with ErbB2, based on expression levels and molecular weight
considerations (Figure 1C).
Knock-down of ErbB2 had no effect on the EGFR degradation
rate in HeLa cells (Figure 2A,B), nor did it influence MAP kinase
(MAPK) signalling as evidenced by immunoblotting with anti-
phospho-MAPK.
Screening for DUBs controlling ErbB2 levels
We screeneda siRNA(siGenome,Dharmacon)libraryforDUBs,
which control the stability of ErbB2, using 29D8 monoclonal
antibody, which recognises an epitope in the cytoplasmic domain.
We then assembled our results into a rank order (Figure 3). The
screen is conducted with a pool of 4 oligos for each DUB. We
selected DUBs at extreme ends of the spectrum of ErbB2 levels for
validation with individual On-Target Plus oligos. 3 DUBs MYSM1,
CSN5 and AMSH-LP showed .1.5 fold increase in ErbB2 in our
initial screen,butinnocase could thisbe confirmed with On-Target
Plus Oligos applied individually. BAP1, USP14, USP2, and POH1
all indicated substantial loss of ErbB2 in the initial screen. Only
POH1 could be convincingly validated, showing significant
decrease in ErbB2 with all four On-Target Plus oligos (Figure 4A).
Whilst small effects on the levels of other RTKs EGFR and Met
were also evident, this was most striking for ErbB2, suggesting some
degree of selectivity (Figure 4A,B). No noticeable change was
observed in the Coomassie Blue staining pattern following POH1
knock-down (not shown), nor in the levels of Transferrin receptor or
the endosome associated proteins STAM and AMSH (Figure 4C).
However, a higher molecular weight form of the ESCRT-0
component Hrs, was evident, which would be consistent with its
mono-ubiquitination (Figure 4C) [19].
Determining the mechanism of ErbB2 loss following
POH1 knock-down
What is the mechanism of this apparent ErbB2 down-regulation
following POH1 knockdown? In principal this could reflect
Figure 1. ErbB2 escapes EGF induced down-regulation. A,
Comparison of ErbB2 receptor levels in HeLa and SKBr3 cells. Cell lysate
samples corresponding to the indicated number of cells were separated
by SDS-PAGE and immunoblotted with ErbB2 antibodies and IR800-
coupled secondary antibodies. The relative amount of ErbB2 per cell
was calculated based on Odyssey scans as discussed in Materials and
Methods. B, HeLa, HEK293T (H293T), A549, and DU145 cells were
stimulated with 100 ng/ml EGF for 2 hours and lysed in parallel with
unstimulated cells. The lysate was subjected to SDS-PAGE and
immunoblotting with EGFR, ErbB2, and tubulin antibodies. EGFR is
down-regulated after 2 hours stimulation, but ErbB2 remains stable. C,
HeLa and SKBr3 cells were treated with 100 ng/ml EGF for 1 or 2 hours
and analysed by immunoblotting with EGFR and ErbB2 antibodies. No
EGFR was detected in SKBr3 cells. Note that EGFR antibody (2232) cross-
reacts with high levels of ErbB2 in SKBr3 cells.
doi:10.1371/journal.pone.0005544.g001
Figure 2. Effects of ErbB2 depletion on EGFR down-regulation
and downstream signaling in HeLa cells. A. HeLa cells were
treated with ErbB2 siRNA or oligofectamine transfection reagent
(control) for 48 hours before stimulation with 100 ng/ml EGF for
various time periods. Lysates were analysed by immunoblotting with
EGFR and ErbB2 antibodies. B. quantitation of A showing EGFR down-
regulation was not significantly affected (data averaged from 3
experiments). C. HeLa cells were treated as in A and incubated with
10 ng/ml EGF for different time periods and lysed. Lysate was analysed
by immunoblotting with ErbB2, pMAPK, MAPK, and tubulin antibodies.
Levels of total MAPK and pMAPK were not affected by ErbB2 knock-
down.
doi:10.1371/journal.pone.0005544.g002
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mination of mRNA levels by RT-PCR revealed a slight decrease
at the 48 hrs time-point, but this is not of the requisite magnitude
(assuming linearity), nor does it exhibit selectivity for ErbB2 over
EGFR (Figure 5). We next measured the rate of loss of ErbB2 and
EGFR following a cycloheximide-induced block to translation.
Knockdown of POH1 gave a modest increase in ErbB2 turnover,
but significantly enhanced the down-regulation of EGFR
(Figure 6A,B). Whilst interesting, these results cannot account for
the preferential loss of ErbB2 at steady state. Levels of Hsp90, a
factor known to control ErbB2 stability [11], were unchanged (not
shown). Using an antibody against an extracellular epitope of
ErbB2, Ab20, we obtained very similar results, however we
noticed the presence of a faint, higher molecular weight smear
specific to POH1 knock-down conditions (Figure 6A top panel)
that is characteristic of ubiquitination. We verified that this
phenomenon was reproduced by all four On-Target Plus oligos
directed against ErbB2 (Figure 6C). Given our failure to find a
substantial defect in ErbB2 transcription or protein degradation
rates, we suspected this higher molecular weight form may
represent ubiquitinated ErbB2 that accumulates upon POH1
knockdown and may be less easily detectable by western blotting
due to its heterologous molecular weight. This effect may be
further compounded by using an antibody directed against an
intracellular epitope (29D8), which may conceivably be masked by
this modification. Indeed, the high molecular weight smear
detected with the extracellular antibody is susceptible to in vitro
protease treatment with the catalytic domain of USP2, a non-
specific DUB that can be used in a similar way to alkaline
phosphatase treatment to query the phosphorylation status of a
protein, and which is able to remove ubiqutin from activated
EGFR, a well-established ubiqutinated protein (Figure 6D).
Concomitantly, removal of ubiqutin by USP2 also leads to a
partial recovery of the ErbB2 signal detected with the intracellular
domain antibody, suggesting regeneration of an epitope that was
previously masked by ubiquitin. A western blotting approach may
thus lead us to misjudge the actual amount of ErbB2 expressed in
these cells. Using fluorescently labelled anti-ErbB2 or anti-EGFR
extracellular antibodies allowed us to measure cell surface ErbB2
and EGFR levels following POH1 knockdown by FACS analysis
(Figure 7A,B). This approach showed only modest reductions in
the levels of both receptors. When the same samples were probed
by western blotting with anti-ErbB2 or anti-EGFR antibodies a
highly significant and preferential loss of ErbB2 is observed, that is
however more striking for the intracellular ErbB2 antibody (29D8)
(Figure 7C).
POH1 depletion and proteasome inhibition
POH1 is a component of the 19S proteasomal lid complex and
its knockdown inhibits proteasome activity [20]. Blotting cell
lysates for ubiquitin revealed an accumulation of ubiquitinated
proteins comparable to that observed in the presence of
proteasome inhibitors, however in distinction to acute proteasome
inhibition (for 6 hours) free ubiquitin levels were not reduced, but
if anything slightly increased (Figure 8). We next asked the
question whether we could reproduce the effects of POH1
depletion on ErbB2 levels by chronic inhibition of proteasome
activity. We titrated epoxomicin in long-term culture to determine
the maximum tolerated dose and analysed the effect on ErbB2
levels. Sustained application of 10 nM epoxomicin recapitulated
the selective loss of ErbB2 seen following POH1 knockdown, with
minimal effect on EGFR levels (Figure 9A), whilst the extracellular
domain antibody, Ab20, again showed a higher molecular weight
smear upon proteasome inhibition (Figure 9B).
Discussion
The degradation rate of activated RTKs may be controlled by
the balance of ubiquitination by E3 ligases (such as c-Cbl) and
DUBs such as AMSH [21,22]. ErbB2 is not reduced following
indirect activation through stimulation of EGFR, but can be
destabilised by CHIP-dependent ubiquitination following dissoci-
ation of Hsp90, the target of Geldanamycin [10,23]. Previous
studies have determined the influence of ErbB2 on acute EGFR
down-regulation following over-expression of ErbB2 [5,6,7]. Here,
we have examined the influence of endogenous ErbB2 on
endogenous EGFR down-regulation in HeLa cells, for which
both receptors are estimated to be expressed at similar levels. In
this instance, we clearly show that depletion of ErbB2 does not
influence EGFR down-regulation kinetics.
Initially we reasoned that tonic DUB activity may contribute to
ErbB2 stability and that we may identify a relevant DUB with a
siRNA screen. This predicts that knockdown of a specific DUB
would lead to decreased ErbB2 levels due to ubiquitin-dependent
degradation. The initial screen using the siGenome pool of 4 oligos
per target identified several candidates, but these did not pass the
second round of validation i.e.$two of four On-Target Plus oligos
recapitulating the effect.
One DUB, POH1, passed our validation study (4/4 oligos).
POH1 is a component of the 19S proteasomal lid complex and has
been suggested to couple recycling of ubiquitin to protein
degradation [24]. Although we see a high degree of loss of ErbB2
following POH1 knock-down, especially when using an antibody
directed at the cytosolic domain, when we assay surface associated
ErbB2 with an extra-cellular directed antibody we do not observe
a corresponding loss of receptor. Furthermore, in these POH1-
depleted cells, Western blotting for ErbB2 with an extracellular
domain directed antibody reveals a higher molecular weight smear
characteristic of ubiquitinated receptor that is susceptible to USP2-
cleavage. Thus, we propose that POH1 is an ErbB2 DUB, which
may oppose constitutive ubiquitination of the receptor.
We can see the accumulation of ubiquitinated ErbB2 under
conditions where proteasome activity is blocked, either by POH1
Figure 3. DUB screen for altered ErbB2 levels in HeLa cells.
siRNA mediated knockdown of DUBs was carried out in HeLa cells
(siRNA at 40 nM). Cells were lysed after 72 hours and analysed by
immunoblotting with ErbB2 antibody. A. The amount of ErbB2 for each
sample was normalized to tubulin and expressed relative to control
(non-targeting oligo) for each DUB contained in the library. B. ErbB2
levels in cells treated with a sub-set of the siGenome DUB library.
doi:10.1371/journal.pone.0005544.g003
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ErbB2 is not rapidly down-regulated by the lysosomal pathway as
happens for example with a truncated EGFR fused to a single
linear ubiquitin [25,26]. Our data however fits with the idea of a
specific domain within ErbB2 that restricts ligand-dependent
degradation independently of ubiquitination status [27].
Our study also indicates that the proteasomal pathway is
unlikely to be a major degradative pathway for ErbB2 under
steady state conditions as we do not see any accumulation of
ErbB2 upon POH1 knockdown as measured by FACS analysis.
Rather we suggest that our results indicate a novel role for POH1
in deubiquitinating ErbB2 that may in fact rescue it from
Figure 4. Multiple POH1 oligos down-regulate ErbB2. A. siRNA mediated knockdown (KD) of candidates was repeated with four individual On
Target Plus oligos incubated with HeLa cells for 48 hours. The results for POH1 were consistent. The knockdown of other candidates (MYSM1, USP14,
BAP1, etc) with four individual oligos failed to show significant effects on ErbB2 levels (results from MYSM1 shown as an example). Lysates were also
probed with EGFR, Met, and tubulin antibodies. The effect of knock-down of POH1 on EGFR and Met levels was much less pronounced than for
ErbB2. B. quantitation of ErbB2, EGFR, and Met receptors for POH1 knockdown cells (averaged from 3 experiments). C. HeLa cells were treated with
POH1 siRNA (four individual oligos) or oligofectamine transfection reagent (control) for 48 hours before lysis and analysed by immunoblotting for
Transferrin receptor (TfR), Hrs, STAM, AMSH, and tubulin. Knock-down of POH1 showed minor effects on the levels of these proteins.
doi:10.1371/journal.pone.0005544.g004
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POH1 may de-ubiquitinate EGFR under steady-state conditions,
in which case the receptor will be rescued from degradation in the
lysosomal pathway. This is consistent with our observation of
enhanced EGFR degradation rate following POH1 knock-down
(Figure 6) and chimes with reports that both EGFR and TrkA
receptor can be deubiquitinated by proteasome associated activity
[28,29]. Note that this enhanced turnover of EGFR is unlikely due
to alterations in ErbB2 levels, as direct depletion of ErbB2 did not
affect the downregulation of EGFR (Figure 2).
Using doses of proteasome inhibitors in which HeLa cells
remain viable, we found that we could recapitulate the apparent
loss of ErbB2 and the selectivity for ErbB2 compared with other
RTKs (EGFR and Met), once again accumulating a higher
molecular weight smear as judged by Western blotting. Marx et al.
have also recently observed diminution of ErbB2 levels in breast
cancer cell lines following application of the proteasome inhibitor
Velcade/Bortezomib [30]. However, in their study of cells
expressing high levels of ErbB2, they report that proteasome
inhibition leads to an intracellular accumulation of remaining
ErbB2 consistent with targeting for lysosomal degradation. In
contrast, we found that both surface and total levels of ErbB2 are
actually little changed in the absence of POH1 activity. We were
also unable to rescue or increase ErbB2 levels using a specific
inhibitor of lysosomal acidification (concanamycin, data not
shown), which is at odds with results obtained with chloroquine
in the above study by Marx et al. It is possible that differences in
cell lines and disparate expression levels of receptors are
responsible for these discrepancies. However this may also suggest
that POH1 knockdown does not simply phenocopy proteasome
inhibition, a fact that is also indicated by the opposite effects of
both treatments on free ubiquitin levels (Figure 8).
A recent study has indicated a synergistic interaction between
an ErbB2 directed monoclonal antibody Herceptin/Trastuzumab
and Velcade with respect to cell death of tissue cultured breast
cancer cells [31]. Further study of this interaction as well as
epidemiological data on responsiveness to Velcade and ErbB2
status is clearly warranted.
Materials and Methods
Antibodies and other reagents
Rabbit polyclonal anti-Met (C-28) and anti-TrfR (H-300), goat
polyclonal (1005) anti-EGFR, FITC conjugated ErbB2 (24D2) and
PE conjugated EGFR (528) antibodies were from Santa Cruz.
Mouse monoclonal anti-ErbB2 antibody (Ab20) was purchased
from Neomarkers. Mouse anti-pMAPK, rabbit anti-ErbB2
(29D8), anti-EGFR (2232), anti-MAPK antibodies were obtained
from Cell Signaling. Mouse monoclonal anti-tubulin and rabbit
anti-ubiquitin (U5379) were from Sigma. Mouse monoclonal anti-
polyubiquitinated proteins (FK1) was from BIOMOL internation-
al. Rabbit anti-POH1 was obtained from Zymed laboratories.
Rabbit anti-Hrs, anti-AMSH, and anti-STAM were described
previously [21,32,33]. Secondary donkey anti-mouse and anti-
rabbit IRDye (680 and 800 nm) antibodies were obtained from
LI-COR. Lactacystin, epoxomicin, and concanamycin were
purchased from Calbiochem. DUB siRNA library (siGenome)
and individual siRNAs were obtained from Dharmacon.
Cell culture and RNAi experiments
All tissue culture reagents were from Invitrogen unless specified.
HeLa, HEK293T, and A549 cells were cultured at 37uC with 5%
CO2 in Dulbecco’s modified Eagle’s medium supplemented with
10% foetal bovine serum and 1% non-essential amino acids.
DU145 and SKBr3 cells were grown under the same conditions in
RPMI and McCoy’s (Sigma) medium respectively. In siRNA
mediated knockdown experiments, HeLa cells were treated with
siRNA oligos at 40–45 nM using Oligofectamine in the absence of
serum. After 4 hours, FBS was added to a final concentration of
10%. siRNA duplexes used are as follows, ErbB2 (sense
UGGAAGAGAUCACAGGUUAUU, antisense 59PUAACCU-
GUGAUCUCUUCCAUU), POH1 OL1 (sense GAACAAGU-
CUAUAUCUCUUUU, antisense 59PAAGAGAUAUAGACUU-
GUUCUU), POH1 OL2 (sense GGCAUUAAUUCAUGGA-
CUAUU, antisense 59PUAGUCCAUGAAUUAAUGCCUU),
POH1 OL3 (sense AGAGUUGGAUGGAAGGUUUUU, anti-
sense 59PAAACCUUCCAUCCAACUCUUU), POH1 OL4
(sense GAUGGUUGUUGGUUGGUAUUU, antisense 59PAU-
ACCAACCAACAACCAUCUU).
Estimation of ErbB2 receptor levels in HeLa cells in
comparison to SKBr3 cells
Two dishes of SKBr3 and HeLa cells were set up in parallel.
Two days later, one dish each was trypsinised and cells counted by
haemocytometer, while each parallel dish was lysed in NP-40 lysis
buffer (0.5% Nonidet P-40, 25 mM Tris/HCl pH7.5, 100 mM
NaCl, 50 mM NaF, protease inhibitors) on ice, and the samples
precleared by centrifugation. The amount of protein per cell was
established by BCA assay and samples were analysed by SDS-
PAGE followed by Western blot.
Cell lysis and immunoblotting
Cells were lysed with either NP-40 lysis buffer on ice or SDS
‘‘hot lysis buffer’’ (1% SDS, 1 mM EDTA, and 50 mM NaF)
Figure 5. POH1 depletion does not differentially affect ErbB2 and EGFR transcription levels. HeLa cells were treated6POH1 siRNA (two
individual oligos) for 24 or 48 hours (left and right panels respectively) before RNA was extracted. Levels of mRNA of EGFR and ErbB2 were calculated
relative to actin mRNA. Graph shows qRT-PCR results averaged from 3 experiments. Error bars show standard deviation.
doi:10.1371/journal.pone.0005544.g005
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cycloheximide. Cells were lysed and analysed by immunoblotting with ErbB2 29D8 and Ab20 antibodies, which recognize intracellular and
extracellular epitopes of ErbB2 respectively, EGFR, and tubulin antibodies. B, quantitation shows that both EGFR (by antibody 1005) and ErbB2 (by
antibodies Ab20 and 29D8) are turned over more rapidly in POH1 knock-down cells (data averaged from 3 experiments). C. HeLa cells were treated
with four On Target Plus oligos (POH1) or with oligofectamine alone for 72 hours before lysis with hot lysis buffer. A higher molecular weight ErbB2
‘‘smear’’ was observed in all 4 knock-down samples. D The high molecular weight smear associated with ErbB2 immuno-reactivity is sensitive to
treatment with a deubiquitinase (USP2). HeLa cells were treated with POH1 siRNA or oligofectamine for 48 hours before lysis in the presence of NEM.
ErbB2 was immunoprecipitated and treated in vitro with USP2 catalytic domain (100 nM, 8 hours, 37uC). Samples were analyzed by immunoblotting
with ErbB2 antibodies targeting extracellular (Ab20) and intracellular (29D8) domains. Note that the smear detected with Ab20 is lost upon USP2
treatment whilst detection with the intracellular domain antibody increases. As a control for USP2 DUB-activity, EGFR was immunoprecipitated from
EGF-stimulated (5 min) HeLa cells and treated in vitro with USP2 catalytic domain before SDS-PAGE and western blotting with anti-Ubiquitin.
doi:10.1371/journal.pone.0005544.g006
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followed by immunoblotting, and finally analysed with a LI-COR
Odyssey 2.1 system.
siRNA DUB screen
HeLa cells were grown in 6-well plates to 30–50% confluency
and then transfected with DUB specific siRNA oligos at 40 nM,
using Oligofectamine (Invitrogen). After 72 hours, cells were lysed
with NP-40 lysis buffer. Lysates were subjected to SDS-PAGE
followed by immunoblotting with ErbB2 (29D8) and tubulin
antibodies. ErbB2 bands were quantified with the LI-COR
Odyssey 2.1 system and ImageJ and normalized to tubulin.
Real time PCR
HeLa cells were treated with control reagent or POH1 siRNA
for 24 or 48 hours. RNA was extracted using a Qiagen RNAeasy
kit. cDNA was prepared with a QuantiTectH reverse transcription
kit (Qiagen). RT-PCR reactions were set up using DyNAmo HS
SYBR Green qPCR kit (Finnzymes) and run on the BioRad iQ5
system according to the manufacturer’s instructions. Experimental
data for EGFR and ErbB2 were normalized to actin.
Flow cytometry
HeLa cells were treated with control reagent or POH1 siRNA
for 48 hours. Cells were detached by incubation at 37uC in PBS
Figure 7. Cell surface levels of ErbB2 are relatively insensitive to POH1 knock-down. A, HeLa cells were treated with ErbB2, POH1 siRNA or
oligofectamine alone for 48 hours before detachment with 2 mM EDTA. One million cells from each condition were labelled with FITC-conjugated
ErbB2 and phycoerythrin (PE) conjugated EGFR antibodies and then analysed by flow cytometry. B, quantification of A shows relative amounts of
fluorescence for each condition. C, samples from A were analysed by immunoblotting with ErbB2 (Ab20 and 29D8), EGFR, POH1, and tubulin
antibodies.
doi:10.1371/journal.pone.0005544.g007
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reaction, which were first washed with PBS supplemented with
0.1% BSA and 0.05% sodium azide (PBS/B/A) and then
incubated with Phycoerythrin conjugated EGFR and fluorescein
isothiocyanate (FITC) conjugated ErbB2 antibodies (Santa Cruz)
for 30 minutes in the same buffer on ice. Cells were washed once
and then resuspended in 0.5 ml of PBS/B/A, finally analysed by
flow cytometry using a FACScan cytometer.
In vitro deubiquitination assay with USP2 catalytic
domain
HeLa cells were treated with POH1 siRNA or control reagent
for 48 hours and lysed in RIPA buffer (10 mM Tris, pH 7.5,
100 mM NaCl, 1% NP-40, 0.1% SDS, 1% sodium deoxycholate,
and 50 mM NaF) supplemented with protease and phosphatase
inhibitors, and 10 mM N-ethylmaleimide (NEM). Cell lysates were
cleared by centrifugation, equal amounts for each condition were
incubated with prewashed protein G agarose and anti-ErbB2
antibody (Ab5, extracellular epitope, Calbiochem) for 2 hours at
4uC. Beads were washed 3 times with RIPA buffer, twice with
deubiquitination assay buffer (50 mM HEPES pH 7.3, 0.5 mM
EDTA) and finally resuspended in 250 ml of deubiquitination
assay buffer with 2 mM DTT. Samples with or without USP2
catalytic domain (100 nM; BIOMOL, UW9850) were incubated
in a thermoshaker for 8 hours (37uC, 1000 rpm). Beads were then
washed twice with 10 mM Tris pH 7.5, proteins eluted with SDS
sample buffer and samples analyzed by immunoblotting with anti-
ErbB2 antibodies recognizing extracellular (Ab20, Neomarkers)
and intracellular (29D8, Cell signaling) epitopes.
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Figure 8. POH1 deletion increases levels of free ubiquitin and ubiquitinated proteins. HeLa cells were treated with POH1 siRNA (oligo 1–
4) or control reagent for 48 or 72 hours before lysis with ‘‘hot lysis’’ SDS-buffer. Equal amounts of cell lysates were analysed by immunoblotting with
A, polyclonal anti-ubiquitin (recognising ubiquitinated proteins and free ubiquitin) and B, FK1 monoclonal anti-ubiquitin (recognising only
polyubiquitinated proteins). As with proteasome inhibitor treatment (Lact: lactacystin, 10 mM and Epo: epoxomicin, 10 mMo r1mM left and right
panels respectively), POH1 depletion caused an accumulation of ubiquitinated proteins in the cell, but in contrast to the inhibitors, which deplete free
ubiquitin, levels of free ubiquitin were elevated.
doi:10.1371/journal.pone.0005544.g008
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